The reiteration of a Neutral rating and maintenance of the price target suggests that Cantor Fitzgerald's view on Sarepta Therapeutics remains unchanged. This stability in analyst sentiment is likely to have a neutral short-term impact on SRPT's stock price, as it does not introduce new positive or negative catalysts.